Recombinant Plasminogen (Rec-PLG)

About Omnio

Omnio is a private, preclinical-stage biotech developing a novel recombinant plasminogen therapy for chronic wounds, starting with diabetic foot ulcers. The company's approach aims to address the underlying biological failure in chronic wounds by clearing damaged tissue, fighting infection, and promoting skin regeneration via a simple subcutaneous injection. With GMP manufacturing and clinical trial applications planned for 2026-2027, Omnio is positioning itself to address a multi-billion euro market with high unmet need.

Therapeutic Areas